162 related articles for article (PubMed ID: 12022937)
1. Fludarabine as second-line therapy for B cell chronic lymphocytic leukaemia: a technology assessment.
Hyde C; Wake B; Bryan S; Barton P; Fry-Smith A; Davenport C; Song F
Health Technol Assess; 2002; 6(2):1-89. PubMed ID: 12022937
[No Abstract] [Full Text] [Related]
2. A challenge to the claims that fludarabine and cyclophosphamide is the new standard treatment for chronic lymphocytic leukaemia.
Haines I; Elliott P; Stanley R
Intern Med J; 2009 Apr; 39(4):269-71. PubMed ID: 19402870
[No Abstract] [Full Text] [Related]
3. Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia.
Walker S; Palmer S; Erhorn S; Brent S; Dyker A; Ferrie L; Horsley W; Macfarlane K; White S; Thomas S
Health Technol Assess; 2009 Jun; 13 Suppl 1():35-40. PubMed ID: 19567212
[TBL] [Abstract][Full Text] [Related]
4. Fludarabine for chronic lymphocytic leukemia.
Marchetti M; Barosi G; Liberato LN
N Engl J Med; 2001 Apr; 344(15):1166-7; author reply 1167-8. PubMed ID: 11302140
[No Abstract] [Full Text] [Related]
5. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche.
Main C; Pitt M; Moxham T; Stein K
Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488
[TBL] [Abstract][Full Text] [Related]
6. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study.
Österborg A; Jewell RC; Padmanabhan-Iyer S; Kipps TJ; Mayer J; Stilgenbauer S; Williams CD; Hellmann A; Furman RR; Robak T; Hillmen P; Trnêný M; Dyer MJ; Piotrowska M; Kozak T; Gupta IV; Phillips JL; Goldstein N; Struemper H; Losic N; Lisby S; Wierda WG;
Haematologica; 2015 Aug; 100(8):e311-4. PubMed ID: 25769539
[No Abstract] [Full Text] [Related]
7. Cost-Effectiveness Model for Chemoimmunotherapy Options in Patients with Previously Untreated Chronic Lymphocytic Leukemia Unsuitable for Full-Dose Fludarabine-Based Therapy.
Becker U; Briggs AH; Moreno SG; Ray JA; Ngo P; Samanta K
Value Health; 2016 Jun; 19(4):374-82. PubMed ID: 27325329
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
Rai KR; Peterson BL; Appelbaum FR; Kolitz J; Elias L; Shepherd L; Hines J; Threatte GA; Larson RA; Cheson BD; Schiffer CA
N Engl J Med; 2000 Dec; 343(24):1750-7. PubMed ID: 11114313
[TBL] [Abstract][Full Text] [Related]
9. Purine analogs in the treatment of chronic lymphocytic leukemia.
Pott C; Hiddemann W
Leukemia; 1997 Apr; 11 Suppl 2():S25-8. PubMed ID: 9178834
[TBL] [Abstract][Full Text] [Related]
10. Fludarabine in chronic lymphocytic leukaemia.
Elter T; Hallek M; Engert A
Expert Opin Pharmacother; 2006 Aug; 7(12):1641-51. PubMed ID: 16872267
[TBL] [Abstract][Full Text] [Related]
11. Acute myeloid leukemia and myelodysplasia in patients with chronic lymphocytic leukemia receiving fludarabine as initial therapy.
Coso D; Costello R; Cohen-Valensi R; Sainty D; Nezri M; Gastaut JA; Bouabdallah R
Ann Oncol; 1999 Mar; 10(3):362-3. PubMed ID: 10355587
[No Abstract] [Full Text] [Related]
12. Fludarabine as a second-line treatment of advanced stage chronic lymphocytic leukemia.
Ayyildiz O; Isikdogan A; Bolaman Z; Muftuoglu E
Saudi Med J; 2004 Dec; 25(12):2054-6. PubMed ID: 15711709
[No Abstract] [Full Text] [Related]
13. [Economic evaluation of rituximab added to fludarabine plus cyclophosphamide versus fludarabine plus cyclophosphamide for the treatment of chronic lymphocytic leukemia].
Casado LF; García Marco JA; Gilsanz F; González M; Ríos E; de la Serna J; Urbano A; Vicente V; Rubio-Terrés C; Castro AJ
Gac Sanit; 2011; 25(4):274-81. PubMed ID: 21664727
[TBL] [Abstract][Full Text] [Related]
14. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis.
Levy V; Porcher R; Delabarre F; Leporrier M; Cazin B; Chevret S;
J Clin Epidemiol; 2001 Jul; 54(7):747-54. PubMed ID: 11438417
[TBL] [Abstract][Full Text] [Related]
15. Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
Richards S
Cancer Treat Rev; 2005 Jun; 31(4):332-5. PubMed ID: 15894429
[No Abstract] [Full Text] [Related]
16. Economic assessment on the management of chronic lymphocytic leukaemia.
Goor KM; Schaafsma MR; Huijgens PC; van Agthoven M
Expert Opin Pharmacother; 2005 Jun; 6(7):1179-89. PubMed ID: 15957971
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine combination therapy for the treatment of chronic lymphocytic leukemia.
Schmitt B; Wendtner CM; Bergmann M; Busch R; Franke A; Pasold R; Schlag R; Hopfinger G; Hiddemann W; Emmerich B; Hallek M
Clin Lymphoma; 2002 Jun; 3(1):26-35. PubMed ID: 12141952
[TBL] [Abstract][Full Text] [Related]
18. [Fludarabine as primary therapeutic drug in chronic lymphatic leukemia].
Hallek M
Internist (Berl); 2002 Apr; 43(4):563-4, 565-6. PubMed ID: 12053413
[No Abstract] [Full Text] [Related]
19. Clinical experience with fludarabine in leukaemia.
Keating MJ; Estey E; O'Brien S; Kantarjian H; Robertson LE; Plunkett W
Drugs; 1994; 47 Suppl 6():39-49. PubMed ID: 7525188
[TBL] [Abstract][Full Text] [Related]
20. Fatal fludarabine-induced extensive bone marrow necrosis in a patient with chronic lymphocytic leukemia.
Braester A; Elmalah Y; Quitt M
Leuk Lymphoma; 2003 Oct; 44(10):1835-6. PubMed ID: 14692545
[No Abstract] [Full Text] [Related]
[Next] [New Search]
